UK Regulators and Patients Watch US Decision on Ozempic Blindness Risk

RecentNews.uk

US regulators require safety updates on GLP-1 medications regarding a rare eye condition.

NAION restricts blood flow to the optic nerve and can cause permanent vision loss.

Clinical data reviewed by the FDA showed 6.4 cases per 100,000 patient-years among users.

Manufacturers maintain that data does not definitively establish a direct causal relationship.

Does this new warning affect your view on taking GLP-1 medications?

Tap below to vote and see what others think.